UPDATE : Thursday, July 18, 2019
상단여백
Seoul revokes sales license of Invossa-K, prosecutes Kolon Life Science by Lee Han-soo 2019-05-28 11:31
Corestem applies for FDA meet on Lou Gehrig's drug by Lee Han-soo 2019-05-27 17:51
Brazil OKs Samsung Bioepis’ trastuzumab biosimilar by Lee Han-soo 2019-05-27 15:52
[Pre-ASCO 2019] Yooyoung Pharmaceutical: YYB101 -- refractory solid tumor treatment by Lee Han-soo 2019-05-27 14:22
HanAll's global partner starts P2 trial of Graves' ophthalmopathy treatment by Lee Han-soo 2019-05-24 14:44
라인
SNUH professor develops candidate substance for subarachnoid hemorrhage by Lee Han-soo 2019-05-23 17:22
Optimal radiotherapy condition found for breast reconstructive surgery patients by Lee Han-soo 2019-05-23 16:13
Asan Medical Center ranks 1st among local hospitals: Newsweek by Lee Han-soo 2019-05-23 15:01
OliX confident of its age-related macular degeneration treatment’s efficacy by Lee Han-soo 2019-05-23 13:48
Prosecutors seek arrest warrant of Samsung BioLogics CEO by Lee Han-soo 2019-05-23 11:19
라인
Sillajen, CHA Hospital to co-develop immunotherapy by Lee Han-soo 2019-05-22 18:26
SK Bioscience's shingles vaccine increases market share by Lee Han-soo 2019-05-22 17:04
Handok, Sanofi to promote vaccines jointly by Lee Han-soo 2019-05-22 15:48
‘Dupixent is sole systemic, long-term treatment for atopic dermatitis’ by Lee Han-soo 2019-05-22 14:44
CMC researchers discover new strategy in treating liver cancer by Lee Han-soo 2019-05-21 17:13
라인
Ministry grants additional indication to MSD’s immunotherapeutic drug by Lee Han-soo 2019-05-21 14:55
[Pre-ASCO 2019] ABL Bio: ABL001- bispecific antibody with indications for anti-cancer therapy by Lee Han-soo 2019-05-21 12:47
Researchers identify novel protein enzymes that repair mutant DNA by Lee Han-soo 2019-05-21 12:00
Roche’s breast cancer drug gains more insurance benefits by Lee Han-soo 2019-05-21 10:44
Bridge Biotherapeutics releases first-in-human study for idiopathic pulmonary fibrosis treatment by Lee Han-soo 2019-05-20 15:29
여백
여백
여백
Back to Top